Viking Therapeutics: A Deep Value Play or a Biotech Bubble? Analyzing VKTX After the Sell-Off
Shares of Viking Therapeutics have retreated sharply from recent highs, presenting a conundrum for investors. While short-term performance lags, long-term gains remain stellar. We delve beyond the headline numbers, using DCF and peer analysis to assess if the current weakness is a buying opportunity.